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Background: The 6 min walk test (6MWT) provides prognostic information in various respiratory
diseases, but limited data exist in cystic fibrosis (CF) adults.
Methods: Consecutive CF adults who performed 6MWT at Cochin Hospital (Paris, France) over
12 years were analyzed. The cut-off 6 min walking distance (6MWD) value that best predicted a
combined endpoint (death without transplant or lung transplant) was established using a
receiver operating curve. Determinants of low 6MWD or of desaturation (SpO2  90%) during
6MWT were examined using multivariate logistic regressions. Prognostic value of these vari-
ables was assessed using KaplaneMeier and Cox analyses.
Results: 6MWT was performed in 286 CF adults (median: age, 28 yr; FEV1, 45% predicted) of
whom 14% (nZ 40) had lung transplant and 6% (nZ 18) died without transplant. 6MWD corre-
lated with FEV1% predicted (rZ 0.43; P < 0.001), but markedly differed in subjects within the
same range of FEV1. A 6MWD 475 m predicted death or transplant and was mostly found in
patients with FEV1 60% predicted. Desaturation during the 6MWT occurred in 29% of patients,
exclusively in subjects with FEV1 60% predicted. Both 6MWD 475 m and desaturation during
the 6MWT were independent predictors of death or transplant.neumologie, Hoˆpital Cochin, 27 rue du Faubourg St Jacques, 75014 Paris, France. Tel.: þ33 1 58 41 23
l@cch.aphp.fr (P.-R. Burgel).
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Cystic fibrosis (CF) in adults is usually characterized by
respiratory disease with bronchiectasis and chronic airway
infection. Structural abnormalities characterized by airway
remodeling and mucus plugging lead to progressive airflow
limitation [1], often resulting in respiratory failure and in
the need for lung transplant [2]. Although a forced expi-
ratory volume in 1 s (FEV1) <30%, a marker of the severity
of airflow limitation, has been initially proposed for
considering lung transplant in CF patients [3], CF patients
with very severe airflow limitation may have prolonged
survival without transplant [4]. Because CF is a multiorgan
disease, it has been suggested that combination of respi-
ratory and extra-respiratory variables may help in the
prognostic evaluation of CF adults [5].
The 6 min walk test (6MWT) is a practical simple test
that evaluates the global and integrated response of all the
systems involved during exercise, including the pulmonary
and cardiovascular systems, systemic circulation, periph-
eral circulation, blood, neuromuscular units, and muscle
metabolisms [6]. The test has been initially used in the
preoperative and postoperative evaluation and in the
evaluation of therapeutic intervention (e.g., pulmonary
rehabilitation) [6]. Subsequently, it has been used to gain
prognostic information in various chronic respiratory dis-
eases including pulmonary hypertension [7], idiopathic
pulmonary fibrosis [8], and chronic obstructive pulmonary
disease (COPD) [9].
The clinical value of 6MWT in CF adults has been seldom
studied. Most studies were performed in small cohorts of
subjects with a narrow range of airflow limitation (either in
subjects with mild airflow limitation [10e12] or in the
evaluation of candidates for lung transplant [13,14]). At
this time, studies of 6MWT in large cohorts of CF adults with
a wide range of airflow limitation have not been performed,
and the prognostic value of the 6MWT in CF adults has not
been established.
The aims of the present study were (A) to describe 6
min walking distance (6MWD) and oxygen saturation (SpO2)
during the 6MWT in a large cohort of adult CF patients with
a wide range of airflow limitation (B) to examine the de-
terminants of a low 6MWD and those of desaturation during
the 6MWT (C) to determine whether data obtained during
the 6MWT provide additional prognostic information
compared to usual predictors of survival.
Methods
Patients
Consecutive CF adults (age > 18 yr) who underwent at least
one 6MWT at Cochin Hospital (Paris, France) from October
2000 to January 2012 were included in the analysis. CF wasdiagnosed on the basis of clinical manifestations, sweat
chloride concentrations and genetic findings [15]. Charac-
teristics were recorded while the patients were in stable
state at the time of the first 6MWT. Data included age,
gender, age at diagnosis of CF, CFTR mutations, pancreatic
status, diabetes mellitus, liver cirrhosis, oxygen depen-
dence, use of non-invasive ventilation, chronic airway
bacterial colonization with Pseudomonas aeruginosa or
Burkholderia cepacia, and body mass index (kg/m2). Vital
status (alive without lung transplant, dead without lung
transplant, transplanted) was assessed as per January 31st
2012. The study conformed to the Declaration of Helsinki
and was approved by the Institutional Review Board of the
French Learned Society for Respiratory MedicineeSocie´te´
de Pneumologie de Langue Franc¸aise- (IRB#, 2012-013).
Six minute walk and pulmonary function tests
The 6MWTwas performed indoors, along a flat straight 50 m
corridor supervised by a trained researcher, according to
the ATS guidelines [6]. A practice 6MWTwas not performed.
All 6MWT were performed with pulse oximetry for contin-
uous recording of oxygen saturation (SpO2). Dyspnea was
assessed using the Borg scale each minute during the 6MWT
and maximum dyspnea level was recorded [6]. Patients
were encouraged every minute using the standardized
recommended sentences: “you are doing well” or “keep up
the good work”. Patients were allowed to stop during the
test, but were instructed to resume the walking as soon as
they felt able to do so. Pulmonary function data were ob-
tained using whole-body plethysmography with standard-
ized equipment (Jaeger) according to ATS/ERS consensus
guidelines. All pulmonary function data were obtained as
absolute values and expressed as % predicted of reference
values [16].
Statistical analysis
Data were reported as median and interquartile range [IQR]
or n (%). The cut-off 6MWD value that best predicted death
without transplant or lung transplant was determined from
a receiver operating curve (ROC), using maximum Youden
indice. Desaturation during the 6MWTwas defined as a SpO2
90% during the test. Univariate and multivariate stepwise
logistic regressions were used to examine which indepen-
dent factors were associated with low 6MWD (475 m) or
with desaturation (SpO2  90%) during 6MWT. All variables
with a P  0.20 in univariate analyses were entered in the
models. Time to death or lung transplant was studied using
KaplaneMeier estimates and comparisons between curves
were performed using a log-rank test. Multivariate analysis
of variables associated with death without transplant or
lung transplant was performed with a Cox proportional
hazard model. In this analysis, FEV1 % predicted was forced
6 min walk test in cystic fibrosis adults 1883into the model to examine which variables provided addi-
tional prognostic information when added to FEV1, a usual
predictor of lung transplantation or mortality in CF patients
[3]. Statistical analyses were 2-sided and P < 0.05 was
considered statistically significant. Analyses were per-




Characteristics of 286 adult CF patients are presented in
Table 1. Very severe airflow limitation (FEV1 < 30% pre-
dicted) was found in 23% (n Z 66) patients, severe airflow
limitation (30  FEV1 < 60% predicted) in 45% (n Z 129)
patients, and moderate airflow limitation (FEV1  60%
predicted) in 32% (nZ 91) patients. SpO2 at rest was 90%
in 6% (n Z 17) patients, including 9 patients with SpO2 at
rest Z 90%, 4 patients with SpO2 at rest Z 89%, and 4
patients with SpO2 at rest 88%. Median [IQR] follow-up
after the 6MWT was 723 [384; 1496] days. At the end of
follow-up, 80% (n Z 228) patients were alive without
transplant, 14% (nZ 40) had received lung transplant, and
6% (n Z 18) had died without transplant.Table 1 Characteristics of 286 adult CF patients.
n Z 286
Age, yr 28.0 [23.0; 33.0]
Age at diagnosis, yr 1.5 [0.2; 10.0]
Male Gender 144 (50)
Body Mass Index, kg/m2 19.7 [18.2; 21.2]
CFTR mutations
F508 del/F508 del 137 (48)
F508 del/other 101 (35)
Other/other 48 (17)
Pancreatic insufficiency 238 (83)
Diabetes 66 (23)
Liver cirrhosis 22 (8)
Airway colonization
Pseudomonas aeruginosa 192 (67)
Burkholderia cepacia 12 (4)
Long-term oxygen therapy 39 (14)
Non-invasive ventilation 15 (5)
Waiting for lung transplant 3 (1)
Pulmonary function tests
FEV1, % predicted 45 [32; 65]
FVC, % predicted 66 [48; 82]
FEV1/FVC, % 0.61 [0.52; 0.70]
FRC, % predicted 131 [114; 152]
RV, % predicted 197 [155; 241]
TLC, % predicted 105 [96; 116]
RV/TLC, % 52 [41; 61]
SpO2 at rest, % 96 [94; 97]
SpO2 at rest 90% 17 (6)
Data are median [IQR] or n (%).
Abbreviations: FEV1: forced expiratory volume in 1 s; FVC:
forced vital capacity, FRC: functional residual capacity; RV:
residual volume; TLC: total lung capacity.Six minute walk test
A six minute walk test was performed in room air in 272
patients. Oxygen supplementation during the test was
provided in 14 patients (all with FEV1 30% predicted),
including 8 patients with SpO2 at rest 89% and in 6 pa-
tients with 90%  SpO2 at rest 92%. All 14 patients who
received oxygen supplementation during the 6MWT had
SpO2 at rest with oxygen supplementation 92%, but
desaturation (SpO2  90%) during the test occurred in all 14
patients (SpO2 min 84 [81e86]%). These latter patients
were kept in the analyses because the exclusion of these
patients with severe disease would have introduced bias in
prognosis analyses.
The median [IQR] 6MWD was 526 [460; 584] m. The
6MWD correlated with FEV1 % predicted (Pearson rZ 0.43;
P < 0.001); median 6MWD were 574 m, 522 m and 458 m in
subjects with moderate, severe and very severe airflow
limitation, respectively. In patients who performed 6MWT
under oxygen supplementation (nZ 14), the median 6 MWD
was 370 m. Marked heterogeneity in 6MWD was found
within each group of patients with similar range of airflow
limitation (see Fig. 1). Based on a receiving operating curve
(see Fig. 2), the cut-off 6MWD value that best predicted
death or lung transplant was 472 m. From a clinical point of
view, we defined a low 6MWD as 475 m. A 6MWD 475 m
was found in 29% (nZ 84) patients, including 59% (nZ 39/
66) patients with FEV1 <30% predicted, 26% (n Z 33/129)
patients with 30%  FEV1 < 60% predicted, and 13%
(n Z 12/91) patients with FEV1 60% predicted
(P < 0.0001, chi-square test). Variables associated with a
6MWD 475 m in univariate and multivariate analyses are
presented in Table 2. In multivariate analysis, only FEV1 %
predicted (P Z 0.0003) and SpO2 at rest (P Z 0.06) were
predictors of 6MWD.
Desaturation, as defined by a SpO2 90% during the
6MWT, was found in 83 (29%) patients, including all patients
(n Z 14) who had oxygen administration during the 6MWT.
The relationship between minimal SpO2 during 6MWT and
FEV1 % predicted is shown in Fig. 3. Although all patients
with desaturation had a FEV1 60% predicted, several pa-
tients with very severe airflow limitation had no desatura-
tion. Variables associated with a SpO2 90% during the
6MWT in univariate and multivariate analyses are presented
in Table 3. In multivariate analysis, variables associated
with desaturation during the 6MWT were SpO2 at rest, FEV1
% predicted, residual volume (RV)/total lung capacity
(TLC), liver cirrhosis and body mass index (BMI).Prognostic value of 6MWD and desaturation during
6MWT
KaplaneMeier analyses of the risk of death or lung trans-
plant according to 6MWD and to SpO2 during 6MWT are
shown in Fig. 4. A 6MWD 475 m or a SpO2 90% during the
6MWT were associated with higher risk of death or lung
transplant (both analyses, P < 0.001). To further examine
whether data obtained during the 6MWT were independent
predictors of death or lung transplant, we performed a Cox
analysis. Multivariate predictors of death or lung transplant
were airway colonization with B. cepacia, 6MWD 475 m,
Figure 1 Distribution of 6MWD according to the severity of
airflow limitation. Adult CF subjects were classified according
to the range of airflow limitation, as follows: very severe
airflow limitation (FEV1, % predicted <30%; n Z 66 patients;
upper panel), severe airflow limitation (30  FEV1, % predicted
<60%; n Z 129 patients; middle panel) and moderate airflow
limitation (FEV1, % predicted 60%; n Z 91 patients; lower
panel). In each group, the distribution of 6MWD followed a
normal distribution (KolmogoroveSmirnov test >0.05).
Figure 2 Receiver operating curve of 6MWD. The receiver
operating curve (ROC) is a mathematical function of the
sensitivity and specificity of the 6MWD. The best value for
death or lung transplant prediction (including 18 deaths and 40
lung transplants) was 472 m, which provided a 60% sensitivity
and 79% specificity. From a clinical perspective, the cut-off
value of 475 m was chosen as representing a low 6MWD.
Table 2 Variables associated with a 6MWD 475 m in
univariate and in multivariate logistic regressions.
Variables Odds ratio [95% CI] P value
Univariate logistic regression
Gender (female vs. male) 0.89 [0.53; 1.48] 0.66
Age, yr 1.02 [0.99; 1.05] 0.20
Pancreatic insufficiency 1.14 [0.57; 2.29] 0.70
Body mass index, kg/m2 0.89 [0.80; 0.99] 0.03
Diabetes 1.44 [0.82; 2.52] 0.20
Liver cirrhosis 0.89 [0.34; 2.37] 0.82
P. aeruginosa colonization 1.56 [0.89; 2.75] 0.12
B. cepacia colonization 2.51 [0.79; 8.03] 0.12
FEV1, %predicted
a 0.62 [0.53; 0.73] <0.0001
FVC, % predicteda 0.64 [0.55; 0.75] <0.0001
RV/TLC, predicteda 1.07 [1.04; 1.10] <0.0001
SpO2 at rest 0.72 [0.65; 0.81] <0.0001
Multivariate logistic regression
FEV1, % predicted
a 0.70 [0.58; 0.85] 0.0003
SpO2 at rest 0.88 [0.76; 1.00] 0.06
a Odds ratio for a 10% increase.
1884 C. Martin et al.SpO2 90% during the 6MWT and level of dyspnea (Borg
scale) during the 6MWT, whereas higher FEV1 % predicted
was associated with improved survival (see Table 4).
Discussion
In the present study, we examined the prognostic value of
6MWT in a large single center cohort of CF adults. We found
that a low 6MWD (475 m) or a desaturation (SpO2 90%)
during the 6MWT were associated with increased risk of
death without transplant or lung transplant. Importantly,
these variables remained associated with death without
transplant or lung transplant in a multivariate Cox analysis
taking into account usual predictors of poor outcome in CF
adults. These data suggest that the 6MWT provides impor-
tant prognostic information in CF adults.
The 6MWD correlated with FEV1 (% predicted), indicating
that exercise capacity decreased with increasing airflow
limitation in CF adults. This finding is consistent with the
results of previous studies that assessed the 6MWD in
smaller cohorts of CF adults. For example, Chetta et al.
reported that the mean SD 6MWD was 626  49 m in 25 CF
adults with moderate airflow limitation (FEV1, 69  23%
predicted) [10], whereas Coloni et al. reported that the
6MWD was 320  90 m in a series of 109 CF adults referred
for lung transplant (FEV1, 20  5% predicted) [13]. In the
present study, the relatively large sample size and the widerange of airflow limitation allowed identifying 6MWD vari-
ability in subjects with similar range of airflow limitation. In
fact, there was considerable overlap in 6MWD between CF
adults with different range of airflow limitation, suggesting
that FEV1 was not the only determinant of 6MWD in CF
adults. Thus, both FEV1 % predicted (PZ 0.003) and SpO2 at
rest (P Z 0.06) were associated with a low 6MWD in
multivariate analysis, whereas other variables including
Figure 3 Relationship of FEV1, % predicted to desaturation
during the 6MWT. Minimal SpO2 during the 6MWT was recorded
and desaturation was defined as a SpO2 90% (vertical line).
Desaturation was observed exclusively in subjects with an FEV1
60% predicted (horizontal line). However, a subgroup of
subjects (lower right quadrant) with an FEV1 <30% predicted
had no desaturation during the 6MWT.
6 min walk test in cystic fibrosis adults 1885age, gender and BMI were not associated with 6MWD. In a
recent study of 64 CF adults with milder airflow limitation
(FEV1 64  20% predicted), Troosters et al. reported sig-
nificant effects of gender, FVC (% predicted), quadricepsTable 3 Variables associated with a desaturation
(SpO2  90%) during the 6MWT in univariate and in multi-
variate logistic regressions.
Variables Odds ratio [95% CI] P value
Univariate logistic regression
Gender (female vs. male) 0.75 [0.45; 1.25] 0.27
Age, yr 1.02 [0.99; 1.05] 0.18
Pancreatic insufficiency 1.28 [0.63; 2.59] 0.50
Body mass index, kg/m2 0.82 [0.73; 0.92] 0.0007
Diabetes 1.48 [0.84; 2.58] 0.17
Liver cirrhosis 2.18 [0.90; 5.26] 0.08
P. aeruginosa colonization 2.16 [1.19; 3.91] 0.01
B. cepacia colonization 0.81 [0.21; 3.06] 0.75
FEV1, % predicted
a 0.32 [0.23; 0.42] <0.0001
FVC, % predicteda 0.40 [0.32; 0.50] <0.0001
RV/TLCa 5.57 [3.53; 8.80] <0.0001
SpO2 at rest 0.48 [0.40; 0.57] <0.0001
Multivariate logistic regression
SpO2 at rest 0.63 [0.51; 0.77] <0.0001
FEV1, % predicted
a 0.56 [0.36; 0.86] 0.008
RV/TLCa 2.18 [1.19; 4.01] 0.01
Liver cirrhosis 3.91 [1.04; 14.7] 0.04
BMI, kg/m2 1.16 [1.00; 1.35] 0.05
a Odds ratio for a 10% increase.force, age and body weight on 6MWD [12]. Differences
between both studies may be, at least in part, related to
baseline characteristics of the cohorts (e.g., number of
patients, severity of airflow limitation) and to the inclusion
of different covariates in the analyses.
Our study revealed that desaturation (SpO2 90%) during
the 6MWT occurred exclusively in subjects with FEV1 60%,
although a group of subjects with very severe airflow limi-
tation (FEV1 <30% predicted) had no desaturation. The
main determinants of desaturation during the 6MWT were
FEV1 % predicted and SpO2 at rest, which were also asso-
ciated with 6MWD. However, the findings that trapped gas
(RV/TLC), nutritional status (BMI) and liver cirrhosis (pre-
sumably through intrapulmonary shunts) were also de-
terminants of desaturation during the 6MWT clearly
indicated that 6MWD and desaturation during the 6MWT
explore different aspects of disease in CF adults.
To the best of our knowledge, the present study is the
first to examine prognostic value of 6MWD in CF adults. We
found that a 6MWD 475 m best predicted death without
transplant or lung transplant. This 6MWD cut-off is mark-
edly higher than the 334 m described to predict mortality in
patients with chronic obstructive pulmonary disease (COPD)
[9] and the 207 m that predicted mortality in patients with
severe idiopathic pulmonary fibrosis (IPF) [17], respec-
tively. The relatively high 6MWD that served as a cut-off to
predict death without transplant or lung transplant in CF
adults is likely explained by the younger age of these sub-
jects compared to those with other chronic respiratory
diseases.
The present study is the largest observational study of
6MWT in CF adults. Although the analysis was retrospective,
all data were prospectively collected and survival infor-
mation was available in all patients. In this single center
study, 6MWT were performed under standardized condition
following international guidelines [6]. Although 6MWD may
vary with demographic characteristics (e.g., age, gender,
body weight or height) in healthy adults [18], no relation-
ship was found between these variables and 6MWD in our
study. Thus, 6MWD was presented in absolute distance
rather than using % predicted of values obtained in healthy
controls [18]. The desaturation cut-off (SpO2 90% during
the 6MWT) that was chosen in this study predicted survival
without transplant. Although the cut-off value was chosen
based on clinical judgment rather than based on statistical
analysis, this criteria provided increased prognostic value
to the 6MWD. The outcome used for prognostic analyses
was death without transplant or lung transplant, reflecting
the fact that most CF patients underwent transplantation
at a time when they had a very high risk of dying. Never-
theless in a sensitivity analysis, we found that a 6MWD
475 m and a SpO2min 90% remained independent pre-
dictors of death (no transplantation, n Z 18) in multivar-
iate analysis (HR 2.80 [1.03; 7.66], P Z 0.04 and HR 3.43
[1.21; 9.67] P Z 0.02, respectively). Finally, the 2002 ATS
statement suggest that a practice 6MWT should be consid-
ered, but no practice 6MWT was performed in the present
study [6]. This recommendation was based on a learning
effect that only increased modestly the 6MWD during a
second 6MWT in most diseases [6]. Ziegler et al. examined
the repeatability of the 6MWT in 31 adolescents and adults
with CF, by performing a first 6MWT followed by a second
Figure 4 KaplaneMeier curves of death or lung transplant according to 6MWD (left panel ) and to minimal SpO2 during the 6MWT
(right panel). A. 6MWD was dichotomized as low 6MWD (475 m) and normal 6MWD (>475 m). B. Desaturation was defined as
SpO290% during the 6MWT. Comparisons between curves were performed using log-rank tests.
1886 C. Martin et al.6MWT after 60 min of rest [19]. The mean difference be-
tween a first and a second test was 6.5 m and the mean
SpO2 difference was 0.6%, indicating that results obtained
during a 6MWT were reproducible [19]. Because 4/31 (13%)
patients had differences in 6MWD that exceeded 54 m, the
authors suggested that two 6MWT are required on any
occasion to obtain a reliable estimate of the 6MWD in CF
patients [19]. Although our data should be interpreted in
this context, the absence of a practice test was present
equally in all patients, which presumably limited the
impact on our conclusion.Table 4 Cox analysis of death without transplant or lung





Gender (female vs. male) 0.79 [0.47; 1.32] 0.37
Age, yr 0.97 [0.94; 1.00] 0.09
Pancreatic insufficiency 3.15 [1.13; 8.75] 0.03
Body mass index, kg/m2 0.77 [0.68; 0.88] 0.0001
Diabetes 1.25 [0.71; 2.21] 0.44
Liver cirrhosis 1.75 [0.74; 4.11] 0.20
P. aeruginosa colonization 1.45 [0.77; 2.75] 0.25
B. cepacia colonization 3.34 [1.51; 7.41] <0.0001
FEV1, % predicted
a 0.46 [0.36; 0.59] <0.0001
FVC, % predicteda 0.52 [0.42; 0.63] <0.0001
RV/TLC,%a 2.79 [1.93; 4.03] <0.0001
SpO2 at rest 0.77 [0.71; 0.83] <0.0001
Data obtained in the 6MWT
6MWD 475 m 3.46 [2.04; 5.86] <0.0001
SpO2 90% during the 6MWT 5.29 [3.00; 9.32] <0.0001
Dyspnea, per 1 point Borg
scale
1.16 [1.05; 1.29] 0.001
Multivariate analysis
FEV1, % predicted
a 0.64 [0.47; 0.88] 0.006
B. cepacia colonization 6.50 [2.41; 17.5] 0.0002
Pancreatic insufficiency 4.02 [1.20; 13.5] 0.03
Data obtained in the 6MWT
6MWD 475 m 2.09 [1.13; 3.90] 0.02
SpO2 90% during the 6MWT 2.00 [0.97; 4.10] 0.06
Dyspnea, per 1 point Borg
scale
1.16 [1.05; 1.29] 0.005
a Hazard ratio for a 10% increase.Assessing the prognosis of CF adults has proven difficult.
Early studies suggested that a FEV1 30% predicted should
prompt lung transplant [3], but further studies showed that
CF adults may have prolonged survival at low lung function
[4]. A comprehensive model that used multiple clinical data
(e.g., age, nutritional status, FEV1, exacerbations, micro-
biological data) provided no better diagnostic accuracy
than the simpler FEV1 criterion for predicting mortality
[20], and predicting poor outcome in CF adults remains a
challenge [21]. Current guidelines for considering lung
transplant in CF adults do not take into account the 6MWT
[5,22]. We suggest that data obtained during the 6MWT may
help in identifying CF adults with severe airflow limitation
who require more intensive therapy and/or assessment for
lung transplant.
In conclusion, our data strongly suggest that the 6MWT
provides important prognostic information in adult CF pa-
tients and should be routinely implemented. This test may
be particularly suited for the prognostic evaluation of
subjects with severe and very severe airflow limitation, as
determined by an FEV1 60% predicted. As previously re-
ported in IPF and in COPD [23,24] future studies should
concentrate on repeating such analysis in multicenter
prospective studies and in evaluating the value of longitu-
dinal assessment of 6MWD to establish the minimal clini-
cally important difference (MCID) associated with poor
outcome. Further, worsening of gas exchange (i.e., SpO2
90%) during the 6MWT in CF patients with severe airflow
limitation who had no desaturation on previous 6MWT may
help in assessment of candidates for lung transplant.
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